Skip to main content
Erschienen in: Endocrine 1/2016

01.04.2016 | Original Article

Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency

verfasst von: Gherardo Mazziotti, Mauro Doga, Stefano Frara, Filippo Maffezzoni, Teresa Porcelli, Luigi Cerri, Roberto Maroldi, Andrea Giustina

Erschienen in: Endocrine | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Cross-sectional studies showed an elevated prevalence of clinical and morphometric vertebral fractures (VFs) in adult patients with growth hormone deficiency (GHD). However, no data are available on incidence and determinants of radiological VFs in this clinical setting. In this prospective study, we investigated the incidence and risk factors of radiological VFs in adults with GHD. Forty patients with GHD (28 males, 12 females; median age 44 years, range 19–82) were studied for incident VFs using quantitative morphometric approach on spine X-ray at baseline and after 6 years of follow-up. GHD patients were also studied for bone mineral density (BMD) measured by DXA at lumbar spine. After 6 years of follow-up, 12 patients (30 %) experienced incident VFs. Patients with incident VFs had more frequently untreated GHD and prevalent VFs at baseline, as compared to patients who did not experience incident VFs. Untreated GHD patients were significantly older as compared to treated GHD (50 years, range 19–82 vs. 36 years, range 19–75; p = 0.003), but the correlation between high risk of VFs and untreated GHD remained significant even after adjustment for the age of patients (odds ratio 6.8, CI 95 % 1.1–41.8; p = 0.037). In GHD patients experiencing incident VFs, lumbar spine BMD decreased significantly whereas it did not change in patients not developing VFs. This is the first prospective study confirming the hypothesis suggested by cross-sectional studies that untreated GHD may cause high risk of VFs in adult patients and that recombinant human GH treatment may effectively decrease such a risk.
Literatur
2.
Zurück zum Zitat A. Giustina, F.F. Casanueva, F. Cavagnini, P. Chanson, D. Clemmons, L.A. Frohman, R. Gaillard, K. Ho, P. Jaquet, D.L. Kleinberg, S.W. Lamberts, G. Lombardi, M. Sheppard, C.J. Strasburger, M.L. Vance, J.A. Wass, S. Melmed, Pituitary Society and the European Neuroendocrine Association., Diagnosis and treatment of acromegaly complications. J. Endocrinol. Invest. 26, 1242–1247 (2003)CrossRefPubMed A. Giustina, F.F. Casanueva, F. Cavagnini, P. Chanson, D. Clemmons, L.A. Frohman, R. Gaillard, K. Ho, P. Jaquet, D.L. Kleinberg, S.W. Lamberts, G. Lombardi, M. Sheppard, C.J. Strasburger, M.L. Vance, J.A. Wass, S. Melmed, Pituitary Society and the European Neuroendocrine Association., Diagnosis and treatment of acromegaly complications. J. Endocrinol. Invest. 26, 1242–1247 (2003)CrossRefPubMed
3.
Zurück zum Zitat A. Giustina, A. Barkan, P. Chanson, A. Grossman, A. Hoffman, E. Ghigo, F. Casanueva, A. Colao, S. Lamberts, M. Sheppard, S. Melmed, Pituitary Society; European Neuroendocrine Association, Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J. Endocrinol. Invest. 31, 820–838 (2008)CrossRefPubMed A. Giustina, A. Barkan, P. Chanson, A. Grossman, A. Hoffman, E. Ghigo, F. Casanueva, A. Colao, S. Lamberts, M. Sheppard, S. Melmed, Pituitary Society; European Neuroendocrine Association, Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J. Endocrinol. Invest. 31, 820–838 (2008)CrossRefPubMed
4.
Zurück zum Zitat S. Melmed, F.F. Casanueva, A. Klibanski, M.D. Bronstein, P. Chanson, S.W. Lamberts, C.J. Strasburger, J.A. Wass, A. Giustina, A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16, 294–302 (2013)CrossRefPubMedPubMedCentral S. Melmed, F.F. Casanueva, A. Klibanski, M.D. Bronstein, P. Chanson, S.W. Lamberts, C.J. Strasburger, J.A. Wass, A. Giustina, A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16, 294–302 (2013)CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat G. Mazziotti, E. Biagioli, F. Maffezzoni, M. Spinello, V. Serra, R. Maroldi, I. Floriani, A. Giustina, Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 100, 384–394 (2015)CrossRefPubMed G. Mazziotti, E. Biagioli, F. Maffezzoni, M. Spinello, V. Serra, R. Maroldi, I. Floriani, A. Giustina, Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 100, 384–394 (2015)CrossRefPubMed
6.
Zurück zum Zitat G. Mazziotti, S. Chiavistelli, A. Giustina, Pituitary diseases and bone. Endocrinol. Metab. Clin. North Am. 44, 171–180 (2015)CrossRefPubMed G. Mazziotti, S. Chiavistelli, A. Giustina, Pituitary diseases and bone. Endocrinol. Metab. Clin. North Am. 44, 171–180 (2015)CrossRefPubMed
7.
Zurück zum Zitat C. Wuster, R. Abs, B.A. Bengtsson, H. Bennmarker, U. Feldt-Rasmussen, E. Hernberg-Ståhl, J.P. Monson, B. Westberg, P. Wilton, KIMS Study Group and the KIMS International Board. Pharmacia & Upjohn International Metabolic Database, The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J. Bone Miner. Res. 16, 398–405 (2001)CrossRefPubMed C. Wuster, R. Abs, B.A. Bengtsson, H. Bennmarker, U. Feldt-Rasmussen, E. Hernberg-Ståhl, J.P. Monson, B. Westberg, P. Wilton, KIMS Study Group and the KIMS International Board. Pharmacia & Upjohn International Metabolic Database, The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J. Bone Miner. Res. 16, 398–405 (2001)CrossRefPubMed
8.
Zurück zum Zitat T. Rosen, L. Wilhelmsen, K. Landin-Wilhelmsen, G. Lappas, B.A. Bengtsson, Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur. J. Endocrinol. 137, 240–245 (1997)CrossRefPubMed T. Rosen, L. Wilhelmsen, K. Landin-Wilhelmsen, G. Lappas, B.A. Bengtsson, Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur. J. Endocrinol. 137, 240–245 (1997)CrossRefPubMed
9.
Zurück zum Zitat H. Holmer, J. Svensson, L. Rylander, G. Johannsson, T. Rosén, B.A. Bengtsson, M. Thorén, C. Höybye, M. Degerblad, M. Bramnert, E. Hägg, B.E. Engström, B. Ekman, K.G. Thorngren, L. Hagmar, E.M. Erfurth, Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J. Bone Miner. Res. 22, 1842–1850 (2007)CrossRefPubMed H. Holmer, J. Svensson, L. Rylander, G. Johannsson, T. Rosén, B.A. Bengtsson, M. Thorén, C. Höybye, M. Degerblad, M. Bramnert, E. Hägg, B.E. Engström, B. Ekman, K.G. Thorngren, L. Hagmar, E.M. Erfurth, Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J. Bone Miner. Res. 22, 1842–1850 (2007)CrossRefPubMed
10.
Zurück zum Zitat D. Mo, M. Fleseriu, R. Qi, N. Jia, C.J. Child, R. Bouillon, D.S. Hardin, Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective cohort study. Lancet Diabetes Endocrinol. 3, 331–338 (2015)CrossRefPubMed D. Mo, M. Fleseriu, R. Qi, N. Jia, C.J. Child, R. Bouillon, D.S. Hardin, Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective cohort study. Lancet Diabetes Endocrinol. 3, 331–338 (2015)CrossRefPubMed
11.
Zurück zum Zitat C. Cooper, E.J. Atkinson, W.M. O’Fallon, L.J. Melton III, Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J. Bone Miner. Res. 7, 221–227 (1992)CrossRefPubMed C. Cooper, E.J. Atkinson, W.M. O’Fallon, L.J. Melton III, Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J. Bone Miner. Res. 7, 221–227 (1992)CrossRefPubMed
12.
Zurück zum Zitat J.F. Griffith, H.K. Genant, New advances in imaging osteoporosis and its complications. Endocrine 42, 39–51 (2012)CrossRefPubMed J.F. Griffith, H.K. Genant, New advances in imaging osteoporosis and its complications. Endocrine 42, 39–51 (2012)CrossRefPubMed
13.
Zurück zum Zitat G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520–528 (2006)CrossRefPubMed G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520–528 (2006)CrossRefPubMed
14.
Zurück zum Zitat G. Mazziotti, T. Porcelli, A. Bianchi, V. Cimino, I. Patelli, C. Mejia, A. Fusco, A. Giampietro, L. De Marinis, A. Giustina, Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur. J. Endocrinol. 163, 15–20 (2010)CrossRefPubMed G. Mazziotti, T. Porcelli, A. Bianchi, V. Cimino, I. Patelli, C. Mejia, A. Fusco, A. Giampietro, L. De Marinis, A. Giustina, Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur. J. Endocrinol. 163, 15–20 (2010)CrossRefPubMed
15.
Zurück zum Zitat G. Mazziotti, A. Bianchi, V. Cimino, S. Bonadonna, P. Martini, A. Fusco, L. De Marinis, A. Giustina, Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. Pituitary 11, 55–61 (2008)CrossRefPubMed G. Mazziotti, A. Bianchi, V. Cimino, S. Bonadonna, P. Martini, A. Fusco, L. De Marinis, A. Giustina, Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. Pituitary 11, 55–61 (2008)CrossRefPubMed
16.
Zurück zum Zitat G. Mazziotti, M. Mormando, A. Cristiano, A. Bianchi, T. Porcelli, A. Giampietro, F. Maffezzoni, V. Serra, L. De Marinis, A. Giustina, Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur. J. Endocrinol. 170, 893–899 (2014)CrossRefPubMed G. Mazziotti, M. Mormando, A. Cristiano, A. Bianchi, T. Porcelli, A. Giampietro, F. Maffezzoni, V. Serra, L. De Marinis, A. Giustina, Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur. J. Endocrinol. 170, 893–899 (2014)CrossRefPubMed
17.
Zurück zum Zitat A. Giustina, G. Mazziotti, Growth hormone replacement therapy and fracture risk. Lancet Diabetes Endocrinol. 3, 307–308 (2015)CrossRefPubMed A. Giustina, G. Mazziotti, Growth hormone replacement therapy and fracture risk. Lancet Diabetes Endocrinol. 3, 307–308 (2015)CrossRefPubMed
18.
Zurück zum Zitat G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877–884 (2010)CrossRefPubMed G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877–884 (2010)CrossRefPubMed
19.
Zurück zum Zitat G. Corneli, C. Di Somma, R. Baldelli, S. Rovere, V. Gasco, C.G. Croce, S. Grottoli, M. Maccario, A. Colao, G. Lombardi, E. Ghigo, F. Camanni, G. Aimaretti, The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index in healthy human subjects. Eur. J. Endocrinol. 153, 257–264 (2005)CrossRefPubMed G. Corneli, C. Di Somma, R. Baldelli, S. Rovere, V. Gasco, C.G. Croce, S. Grottoli, M. Maccario, A. Colao, G. Lombardi, E. Ghigo, F. Camanni, G. Aimaretti, The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index in healthy human subjects. Eur. J. Endocrinol. 153, 257–264 (2005)CrossRefPubMed
20.
Zurück zum Zitat A. Giustina, S. Bossoni, C. Bodini, A. Girelli, G.P. Balestrieri, G. Pizzocolo, W.B. Wehrenberg, Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy. J. Clin. Endocrinol. Metab. 74, 1301–1305 (1992)PubMed A. Giustina, S. Bossoni, C. Bodini, A. Girelli, G.P. Balestrieri, G. Pizzocolo, W.B. Wehrenberg, Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy. J. Clin. Endocrinol. Metab. 74, 1301–1305 (1992)PubMed
21.
Zurück zum Zitat J.A. Kanis, E.V. McCloskey, H. Johansson, O. Strom, F. Borgstrom, A. Oden, National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos. Int. 19, 1395–1408 (2008)CrossRefPubMed J.A. Kanis, E.V. McCloskey, H. Johansson, O. Strom, F. Borgstrom, A. Oden, National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos. Int. 19, 1395–1408 (2008)CrossRefPubMed
22.
Zurück zum Zitat M.E. Molitch, D.R. Clemmons, S. Malozowski, G.R. Merriam, M.L. Vance, Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1587–1609 (2001)CrossRef M.E. Molitch, D.R. Clemmons, S. Malozowski, G.R. Merriam, M.L. Vance, Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1587–1609 (2001)CrossRef
23.
Zurück zum Zitat H.K. Genant, M. Jergas, L. Palermo, M. Nevitt, R.S. Valentin, D. Black, S.R. Cummings, Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 11, 984–996 (1996)CrossRefPubMed H.K. Genant, M. Jergas, L. Palermo, M. Nevitt, R.S. Valentin, D. Black, S.R. Cummings, Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 11, 984–996 (1996)CrossRefPubMed
24.
Zurück zum Zitat J.T. Schousboe, J.A. Shepherd, J.P. Bilezikian, S. Baim, Executive summary of the 2013 International Society for Clinical Densitometry position development conference on bone densitometry. J. Clin. Densitom. 16, 455–466 (2013)CrossRefPubMed J.T. Schousboe, J.A. Shepherd, J.P. Bilezikian, S. Baim, Executive summary of the 2013 International Society for Clinical Densitometry position development conference on bone densitometry. J. Clin. Densitom. 16, 455–466 (2013)CrossRefPubMed
25.
Zurück zum Zitat H.R. Boquete, P.G. Sobrado, H.L. Fideleff, A.M. Sequera, A.V. Giaccio, M.G. Suarez, G.F. Ruibal, M. Miras, Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. J. Clin. Endocrinol. Metab. 88, 4702–4708 (2003)CrossRefPubMed H.R. Boquete, P.G. Sobrado, H.L. Fideleff, A.M. Sequera, A.V. Giaccio, M.G. Suarez, G.F. Ruibal, M. Miras, Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. J. Clin. Endocrinol. Metab. 88, 4702–4708 (2003)CrossRefPubMed
26.
Zurück zum Zitat A.H. Souza, M.I. Farias, R. Salvatori, G.M. Silva, J.A. Santana, F.A. Pereira, F.J. de Paula, E.H. Valença, E.V. Melo, R.A. Barbosa, R.M. Pereira, M.B. Gois-Junior, M.H. Aguiar-Oliveira, Lifetime, untreated isolated GH deficiency due to a GH-releasing hormone receptor mutation has beneficial consequences on bone status in older individuals, and does not influence their abdominal aorta calcification. Endocrine 47, 191–197 (2014)PubMed A.H. Souza, M.I. Farias, R. Salvatori, G.M. Silva, J.A. Santana, F.A. Pereira, F.J. de Paula, E.H. Valença, E.V. Melo, R.A. Barbosa, R.M. Pereira, M.B. Gois-Junior, M.H. Aguiar-Oliveira, Lifetime, untreated isolated GH deficiency due to a GH-releasing hormone receptor mutation has beneficial consequences on bone status in older individuals, and does not influence their abdominal aorta calcification. Endocrine 47, 191–197 (2014)PubMed
27.
Zurück zum Zitat T. Jalava, S. Sarna, L. Pylkkänen, B. Mawer, J.A. Kanis, P. Selby, M. Davies, J. Adams, R.M. Francis, J. Robinson, E. McCloskey, Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Miner. Res. 18, 1254–1260 (2003)CrossRefPubMed T. Jalava, S. Sarna, L. Pylkkänen, B. Mawer, J.A. Kanis, P. Selby, M. Davies, J. Adams, R.M. Francis, J. Robinson, E. McCloskey, Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Miner. Res. 18, 1254–1260 (2003)CrossRefPubMed
28.
Zurück zum Zitat R. Lindsay, S. Pack, Z. Li, Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos. Int. 16, 306–312 (2005)CrossRefPubMed R. Lindsay, S. Pack, Z. Li, Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos. Int. 16, 306–312 (2005)CrossRefPubMed
29.
Zurück zum Zitat M.C. Nevitt, B. Ettinger, D.M. Black, K. Stone, S.A. Jamal, K. Ensrud, M. Segal, H.K. Genant, S.R. Cummings, The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann. Intern. Med. 128, 793–800 (1998)CrossRefPubMed M.C. Nevitt, B. Ettinger, D.M. Black, K. Stone, S.A. Jamal, K. Ensrud, M. Segal, H.K. Genant, S.R. Cummings, The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann. Intern. Med. 128, 793–800 (1998)CrossRefPubMed
30.
Zurück zum Zitat J.A. Cauley, M.C. Hochberg, L.Y. Lui, L. Palermo, K.E. Ensrud, T.A. Hillier, M.C. Nevitt, S.R. Cummings, Long-term risk of incident vertebral fractures. JAMA 299, 2761–2767 (2007)CrossRef J.A. Cauley, M.C. Hochberg, L.Y. Lui, L. Palermo, K.E. Ensrud, T.A. Hillier, M.C. Nevitt, S.R. Cummings, Long-term risk of incident vertebral fractures. JAMA 299, 2761–2767 (2007)CrossRef
31.
Zurück zum Zitat H. Johansson, A. Odén, E.V. McCloskey, J.A. Kanis, Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. Osteoporos. Int. 25, 235–241 (2014)CrossRefPubMed H. Johansson, A. Odén, E.V. McCloskey, J.A. Kanis, Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. Osteoporos. Int. 25, 235–241 (2014)CrossRefPubMed
32.
Zurück zum Zitat G. Mazziotti, A. Bianchi, T. Porcelli, M. Mormando, F. Maffezzoni, A. Cristiano, A. Giampietro, L. De Marinis, A. Giustina, Vertebral fractures in patients with acromegaly: a 3-year prospective study. J. Clin. Endocrinol. Metab. 98, 3402–3410 (2013)CrossRefPubMed G. Mazziotti, A. Bianchi, T. Porcelli, M. Mormando, F. Maffezzoni, A. Cristiano, A. Giampietro, L. De Marinis, A. Giustina, Vertebral fractures in patients with acromegaly: a 3-year prospective study. J. Clin. Endocrinol. Metab. 98, 3402–3410 (2013)CrossRefPubMed
33.
Zurück zum Zitat M. Barake, A. Klibanski, N.A. Tritos, Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 852–860 (2014)PubMed M. Barake, A. Klibanski, N.A. Tritos, Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 852–860 (2014)PubMed
34.
Zurück zum Zitat C. Ohlsson, B.A. Bengtsson, O.G. Isaksson, T.T. Andreassen, M.C. Slootweg, Growth hormone and bone. Endocr. Rev. 19, 55–79 (1998)PubMed C. Ohlsson, B.A. Bengtsson, O.G. Isaksson, T.T. Andreassen, M.C. Slootweg, Growth hormone and bone. Endocr. Rev. 19, 55–79 (1998)PubMed
35.
Zurück zum Zitat E. Canalis, A. Giustina, J.P. Bilezikian, Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905–916 (2007)CrossRefPubMed E. Canalis, A. Giustina, J.P. Bilezikian, Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905–916 (2007)CrossRefPubMed
36.
Zurück zum Zitat M.C. Nevitt, S.R. Cummings, K.L. Stone, L. Palermo, D.M. Black, D.C. Bauer, H.K. Genant, M.C. Hochberg, K.E. Ensrud, T.A. Hillier, J.A. Cauley, Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J. Bone Miner. Res. 20, 131–140 (2005)CrossRefPubMed M.C. Nevitt, S.R. Cummings, K.L. Stone, L. Palermo, D.M. Black, D.C. Bauer, H.K. Genant, M.C. Hochberg, K.E. Ensrud, T.A. Hillier, J.A. Cauley, Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J. Bone Miner. Res. 20, 131–140 (2005)CrossRefPubMed
37.
Zurück zum Zitat G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41, 58–69 (2012)CrossRefPubMed G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41, 58–69 (2012)CrossRefPubMed
Metadaten
Titel
Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency
verfasst von
Gherardo Mazziotti
Mauro Doga
Stefano Frara
Filippo Maffezzoni
Teresa Porcelli
Luigi Cerri
Roberto Maroldi
Andrea Giustina
Publikationsdatum
01.04.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2016
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0738-z

Weitere Artikel der Ausgabe 1/2016

Endocrine 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.